Autopsy report · NCT05716295

A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors

“Corporate decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 3 months before it stopped.
• 26 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Medikine, Inc.

Sponsor type

Industry

Conditions

Advanced or Metastatic Solid Tumors

Interventions

MDK-703; Checkpoint Inhibitor, Immune

Participants

26

Sites

6

Countries

United States

Trials that died the same way

• Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy
  “Company decision” (90% match in meaning)
• 3D011-08 Monotherapy in Subjects With Advanced Solid Tumors
  “Company's decision” (88% match in meaning)
• V-Chordal Adjustable System for Chordal Replacement in Mitral Valve Insufficiency Due to Leaflet Prolapse
  “Company business decision” (86% match in meaning)
• Evaluation of Inducible Monomorphic Ventricular Tachycardia (MMVT) in Patients With St. Jude Medical (SJM) Implantable Cardioverter Defibrillator (ICD) Systems or Cardiac Resynchronization Therapy Defibrillation (CRT-D) Systems.
  “Business decision” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.